FDA Clearance of FK-PC101, a Novel Personalized Prostate Cancer Immunotherapy

[Maxone73]

not for stage 4 fighters...but still...

"The trial, CELLVX-230, is a randomized, multicenter, open-label study of irradiated autologous cellular vaccine in men with high-risk prostate cancer post-radical prostatectomy. It will be conducted through a partnership with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), with Scott Eggener, MD (University of Chicago) as Principal Investigator. Patient recruitment will begin in March 2024, with a goal of up to 230 participants sourced from 21 pre-selected sites across the US."

finance.yahoo.com/news/cell...

[Cactus297]

Too bad that Stage 4 can’t be included!

[Maxone73 in reply to Cactus297]

not yet at least

[Cackalacky_cyclist]

I wonder if they would accept someone not yet at BCR, but on the way, or just at BCR when they start recruitment in March.

[Justfor_ in reply to Cackalacky_cyclist]

My guess is that they will recruit high risk patients right after their prostatectomy, so that the tumour samples to be processed and irradiated are "fresh".

[Maxone73]

I think we should create the "guinea pig right" where a patient (guided by an oncologist) takes full responsibility in using a new treatment or even an established one but for a different cancer stage. This would speed up research as well. I know a few guys who would have used Pluvicto as first line with ADT when they were hormone sensitive.